Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b open-label selinexor study in relapsed or refractory diffuse large B-cell lymphoma
MOH_2017-07-12_000624Phase 2Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in diffuse large B-cell lymphoma (DLBCL), sponsored by Karyopharm Therapeutics Inc. Started Jan 2015; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2017-07-12_000624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-12_000624.